Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
16,281 results
  • Efficacy of Brincidofovir as prophylaxis against HSV and VZV in hematopoietic cell transplant recipients. [Journal Article]
  • TITranspl Infect Dis 2018 Aug 18; :e12977
  • Lee YJ, Neofytos D, … Papanicolaou GA
  • CONCLUSIONS: The overall rate of breakthrough HSV infection was 1.0 per 1,000 patient-days, without any breakthrough VZV infections. Our study provides the only available -albeit limited- evidence on the potential efficacy of BCV for HSV/VZV prophylaxis in HCT patients. Additional studies are needed to further assess the efficacy and safety of BCV in the setting. This article is protected by copyright. All rights reserved.
  • Review for Disease of the Year: Treatment of Viral Anterior Uveitis: A Perspective. [Journal Article]
  • OIOcul Immunol Inflamm 2018 Aug 10; :1-8
  • Zandi S, Bodaghi B, Garweg JG
  • CONCLUSIONS: Oral acyclovir, valacyclovir, and famciclovir are the mainstay of treatment for HSV- and VZV-induced infections. Brivudin serves as an alternative in insufficiently responsive cases. CMV-induced infections respond well to valganciclovir. A 3- to 12-month course of prophylactic treatment against recurrences is worth considering.
New Search Next